Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
Authors:
Open Access
- 13 August 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Abstract
Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade ≥ 3 ICI-ILD. The 30-day mortality rate of patients with grade ≥ 3 ICI-ILD was the highest among all patients (P < 0.01). The multivariate logistic analysis indicated that the performance status ≥ 2 alone and both performance status ≥ 2 and ≥ 50 pack-year were independent risk factors of ICI-ILD of grade ≥ 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence.Keywords
Funding Information
- JSPS KAKENHI (19K16414)
- Foundation for Promotion of Cancer Research in Japan
This publication has 35 references indexed in Scilit:
- A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancerTranslational Lung Cancer Research, 2020
- Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitisThoracic Cancer, 2019
- Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reportsBMC Cancer, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case seriesAnnals of the Rheumatic Diseases, 2017
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaJournal for ImmunoTherapy of Cancer, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Interleukin-23/Th17 pathways and inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Serum levels of tumour necrosis factor-α and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate - preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapyEuropean Journal of Cancer Care, 2008